NCT02366273 is a clinical trial of PASI and HOMA index in Diabetes, sponsored by University of Pavia.

Who is sponsoring NCT02366273?

NCT02366273 is sponsored by University of Pavia.

What drugs are being tested in NCT02366273?

Interventions in NCT02366273: PASI and HOMA index.

What condition does NCT02366273 study?

NCT02366273 studies Diabetes, Psoriasis.

Is NCT02366273 still recruiting?

NCT02366273 is currently completed. Last updated 24 May 2022.

Last reviewed 2022-05-24 · How we verify

NCT02366273

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diabetes and Psoriasis

Completed Last updated 24 May 2022

What this trial tests

trial testing PASI and HOMA index in Diabetes in 425 participants. Completed in 30 June 2018.

Timeline

1 February 2015

Primary endpoint
28 February 2018

30 June 2018

Quick facts

Lead sponsor	University of Pavia
Status	Completed
Study type	OBSERVATIONAL
Enrollment	425
Start date	1 February 2015
Primary completion	28 February 2018
Estimated completion	30 June 2018
Sites	1 location across Italy

Drugs / interventions tested

PASI and HOMA index

Conditions studied

Diabetes — all drugs for Diabetes →
Psoriasis — all drugs for Psoriasis →

Sponsor

University of Pavia

Who can join

Eligibility, any sex, with Diabetes or Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with psoriasis will be evaluated. The investigators will collect personal history, concomitant diseases and in particular the presence of type 2 diabetes mellitus, impaired fasting glucose and impaired glucose tollerance. The aim of the study will be to evaluate if there is a correlation among inflammation, insulin-resistance and psoriasis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other University of Pavia trials

Trials by the same sponsor.

NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
NCT07421128 — The Pause, Learn, and Activate Yourself (PLAY) · NA · not yet recruiting
NCT07199712 — Ozone Therapy for Oral Mucositis in Patients Receiving Head and Neck Cancer Radio- and Chemotherapy · NA · completed
NCT07088653 — Comparison of 0.12% Chlorhexidine and MicroRepair ABX Mouthwash in Gingivitis Management · NA · completed
NCT07140146 — Trehalose vs Glycine Air-Polishing in Peri-Implant Mucositis Treatment · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02366273 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pavia
Last refreshed: 24 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02366273.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing